Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date on information about hepatitis and to answer some of our web site and training audience questions. People are encouraged to submit questions and post comments.

For more information on how to use this blog, the HCV drug pipeline, and for more information on HCV clinical trials click here

Be sure to check out our other blogs: The HBV Advocate Blog and Hepatitis & Tattoos.


Alan Franciscus

Editor-in-Chief

HCV Advocate


Wednesday, January 14, 2015

Merck to Seek Approval of New Hepatitis C Drug by Midyear

If all goes as planned, Merck will soon take a major step forward in the hot pursuit among pharmaceutical companies to produce a newer, better, faster-working drug to treat the millions of people who have chronic hepatitis C infection.

By midyear the company expects to submit a New Drug Application to the Food and Drug Administration for approval of grazoprevir/elbasvir, a combination regimen investigational drug designed to be taken once daily as treatment of chronic hepatitis C virus infection. Grazoprevir is an NS3/4A second-generation protease inhibitor and elbasvir is an NS5A inhibitor.

 - See more at: http://www.hcplive.com/articles/Merck-to-Seek-Approval-of-New-Hepatitis-C-Drug-by-Midyear#sthash.maxgPR9Q.dpuf
Posted by at
Labels: ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)